Menu
Back to Journals » Clinical and Experimental Gastroenterology » Volume 7
Management of inflammatory bowel disease in poor responders to infliximab
Authors Guerra I, Bermejo F
Received 16 April 2014
Accepted for publication 11 June 2014
Published 18 September 2014 Volume 2014:7 Pages 359—367
DOI https://doi.org/10.2147/CEG.S45297
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Iván Guerra, Fernando Bermejo
Gastroenterology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain
Abstract: Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's disease and ulcerative colitis patients. Some patients present lack of response or loss of response to IFX during maintenance therapy. Empirical management with combination therapy with an immunomodulator, IFX dose escalation, or switching IFX for another antitumor necrosis factor-α drug, mainly adalimumab, is common in clinical practice. Selecting the best choice with the help of serum drug concentrations and trough IFX antibody concentrations could be a very interesting approach. In addition to surgery, a broad spectrum of new drugs has been tested and could expand treatment options in the near future.
Keywords: inflammatory bowel disease, Crohn's disease, ulcerative colitis, anti-TNF, infliximab, treatment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.